Residency · Residency · Radiation Oncology

Accelerated Partial Breast Irradiation (APBI)

Overview

Accelerated partial breast irradiation (APBI) focuses radiation treatment exclusively on the lumpectomy cavity plus a surrounding margin, rather than irradiating the entire breast. This approach is based on the observation that 60-80% of ipsilateral breast tumor recurrences occur at or near the original tumor bed, meaning that most of the breast tissue does not derive benefit from whole breast irradiation (WBI). By limiting the treatment volume, APBI significantly shortens the duration of therapy from the conventional 3-5 weeks to one week or less, thereby enhancing patient convenience and optimizing healthcare resource utilization. Several techniques are available for delivering APBI, including multicatheter interstitial brachytherapy, balloon-based brachytherapy, external beam radiation therapy (using 3D conformal radiation therapy [3D-CRT] or intensity-modulated radiation therapy [IMRT]), and intraoperative radiation therapy (IORT). Careful patient selection is essential to ensure that outcomes with APBI are comparable to those achieved with WBI.

Patient Selection

ASTRO Consensus Guidelines (2017 Update)

The American Society for Radiation Oncology (ASTRO) categorizes patients into "suitable," "cautionary," and "unsuitable" groups for APBI based on clinical and pathological features. The "suitable" category represents the best candidates for APBI and includes patients aged 50 years or older with invasive ductal carcinoma or favorable ductal carcinoma in situ (DCIS). Tumors should be 2.5 cm or smaller (Tis or T1), unicentric, with negative margins of at least 2 mm, and no nodal involvement (N0). These tumors are typically estrogen receptor (ER) positive, with no lymphovascular space invasion (LVSI) and no known BRCA mutation.

The "cautionary" category includes patients aged 40-49 years, tumors measuring 2.1 to 3.0 cm, cases with limited or focal LVSI, close surgical margins between 1 and 2 mm, ER-negative tumors, and pure DCIS lesions up to 3 cm with margins of at least 3 mm. These patients may be considered for APBI with caution.

Patients classified as "unsuitable" for APBI, who should instead receive WBI, include those younger than 40 years, those with positive surgical margins, multicentric disease, extensive LVSI, node-positive disease, or known carriers of BRCA1 or BRCA2 mutations.

ESTRO/GEC-ESTRO Guidelines

The European Society for Radiotherapy and Oncology (ESTRO) and the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) guidelines align closely with ASTRO’s criteria, emphasizing low-risk features for APBI candidacy. These guidelines tend to be somewhat more permissive regarding DCIS compared to the earlier ASTRO recommendations.

Techniques

Multicatheter Interstitial Brachytherapy

Multicatheter interstitial brachytherapy is the most extensively studied APBI technique and has the longest follow-up data available. This method involves placing multiple catheters through the breast tissue surrounding the lumpectomy cavity. High-dose-rate (HDR) brachytherapy typically delivers 34 Gy in 10 fractions twice daily over five days, with a 4-6 hour interval between fractions. Historically, low-dose-rate (LDR) brachytherapy was administered as 45-50 Gy over 4-5 days. The GEC-ESTRO trial randomized patients to multicatheter brachytherapy APBI versus WBI in low-risk patients and demonstrated non-inferior five-year ipsilateral breast tumor recurrence (IBTR) rates. When performed by experienced teams, this technique yields excellent cosmetic outcomes. However, it requires significant technical expertise and is less widely available than other methods.

Balloon-Based Brachytherapy (MammoSite, SAVI, Contura)

Balloon-based brachytherapy involves placing a single-lumen (MammoSite) or multi-lumen (SAVI, Contura) balloon catheter into the lumpectomy cavity. HDR dosing is similar to multicatheter brachytherapy, with 34 Gy delivered in 10 fractions twice daily over five days. Adequate skin-to-balloon distance, at least 7 mm, is necessary to minimize skin toxicity. The multi-lumen devices such as SAVI and Contura allow for dose shaping, which improves sparing of the skin and ribs. Large registry data, including the American Society of Breast Surgeons (ASBS) MammoSite Registry, report acceptable IBTR rates ranging from 2% to 4% at five years in selected patients.

External Beam APBI (3D-CRT or IMRT)

External beam APBI is a non-invasive technique that uses multiple conformal photon beams to target the lumpectomy cavity plus a margin. The NSABP B-39/RTOG 0413 trial compared 38.5 Gy delivered in 10 fractions twice daily over five days using either external beam or brachytherapy APBI versus standard WBI. The trial found APBI to be non-inferior to WBI for IBTR at 10 years, although there was a slightly higher IBTR rate with APBI (4.6% versus 3.9%). Cosmesis was slightly better with WBI compared to external beam APBI, but the differences were modest. The IMPORT LOW trial randomized patients to 40 Gy in 15 fractions targeting the partial breast (tumor bed plus 1 cm margin), reduced-dose whole breast, or standard WBI. The partial breast irradiation arm was non-inferior for IBTR and demonstrated improved cosmesis and lower toxicity. Prone positioning during external beam APBI may further reduce cardiac and lung radiation exposure.

Intraoperative Radiation Therapy (IORT)

IORT delivers a single radiation fraction at the time of lumpectomy before wound closure. The TARGIT-A trial used 20 Gy delivered with 50 kV X-rays via the Intrabeam device and showed non-inferiority to WBI for local recurrence in the pre-pathology stratum at five years. Although IBTR rates were higher with IORT, overall mortality was equivalent or improved, possibly due to fewer non-breast cancer deaths. These results remain controversial, with ongoing debate about long-term outcomes. The ELIOT trial delivered 21 Gy in a single fraction using mobile linear accelerator electrons and reported higher IBTR rates than WBI (4.4% versus 0.4% at five years), though the pre-specified non-inferiority margin was met. Patients with favorable features had acceptable outcomes. The main advantage of IORT is the convenience of completing radiation in a single treatment during surgery. However, if final pathology reveals unfavorable features, additional WBI may be necessary, partially negating this convenience.

Clinical Trial Evidence Summary

NSABP B-39/RTOG 0413

This is the largest randomized trial evaluating APBI, enrolling 4,216 patients. It compared APBI delivered via external beam or brachytherapy to WBI. At 10 years, the IBTR rate was 4.6% for APBI versus 3.9% for WBI, meeting criteria for non-inferiority. There were no significant differences in disease-free survival (DFS) or overall survival (OS), confirming APBI as an acceptable alternative in selected patients.

GEC-ESTRO Multicatheter Trial

This trial randomized 1,184 patients to multicatheter brachytherapy APBI versus WBI. Five-year IBTR rates were 1.4% for APBI and 0.9% for WBI, demonstrating non-inferiority. Both arms showed excellent cosmetic outcomes. This trial provides the strongest evidence supporting brachytherapy-based APBI.

IMPORT LOW

Involving 2,018 patients, this trial randomized participants to standard WBI, reduced-dose WBI, or partial breast radiation only. The partial breast arm received 40 Gy in 15 fractions targeting the tumor bed plus a 1 cm margin. Five-year IBTR rates were 1.1% for partial breast irradiation versus 0.5% for WBI, establishing non-inferiority. The partial breast approach also resulted in improved breast appearance and reduced toxicity.

Treatment Planning Considerations

Target Volume (External Beam APBI)

The clinical target volume (CTV) for external beam APBI includes the lumpectomy cavity, identified by seroma or surgical clips, plus a 1 to 1.5 cm margin. This volume is cropped 5 mm from the skin surface and the chest wall-lung interface to minimize toxicity. The planning target volume (PTV) is created by adding an additional 0.5 to 1.0 cm margin to the CTV, depending on the image-guided radiation therapy (IGRT) capabilities. For optimal cosmetic outcomes, the ratio of PTV to the whole breast reference volume should ideally be less than 25%.

Quality Metrics

Dose homogeneity within the target is important, with efforts to minimize hotspots exceeding 110% of the prescribed dose. The volume of breast tissue receiving 50% of the prescription dose (V50%) correlates with cosmetic outcomes. Dose constraints for the ipsilateral lung, heart, skin, and ribs are similar to those used in WBI but are generally more favorable due to the smaller treatment volume.

<image>An illustration comparing four APBI techniques in cross-section through the breast at the level of the lumpectomy cavity. Panel A shows multicatheter interstitial brachytherapy with multiple catheters surrounding the cavity and isodose lines. Panel B shows a balloon-based device (SAVI) within the cavity with dose distribution. Panel C shows external beam 3D-CRT with multiple non-coplanar beams converging on the tumor bed CTV. Panel D shows intraoperative RT with the applicator sphere in the open lumpectomy cavity delivering a single fraction. Each panel includes typical dose prescription and fractionation.</image>

<image>A Venn diagram-style infographic showing the ASTRO patient selection categories for APBI: "Suitable" (green center circle with criteria listed), "Cautionary" (yellow ring), and "Unsuitable" (red outer ring). Key distinguishing factors (age, tumor size, margin status, ER status, nodal status, LVSI, BRCA mutation) are annotated along the boundaries between categories.</image>

<image>A bar graph comparing 5-10 year ipsilateral breast tumor recurrence rates across major APBI randomized trials (GEC-ESTRO, NSABP B-39, IMPORT LOW, TARGIT-A, ELIOT). Each trial has paired bars for WBI (blue) and APBI (orange), with the non-inferiority margin annotated. Below the graph, a summary row indicates whether non-inferiority was met for each trial.</image>

Key Clinical Pearls

Patient selection remains the most critical factor influencing APBI outcomes. Ideal candidates are those classified as "suitable" by ASTRO guidelines, typically patients aged 50 years or older with T1, ER-positive, node-negative tumors, negative surgical margins, and no LVSI. Among the various APBI techniques, multicatheter brachytherapy boasts the longest track record and the strongest randomized evidence, particularly from the GEC-ESTRO trial. External beam APBI is supported by robust data from the NSABP B-39 and IMPORT LOW trials. Intraoperative radiation therapy (IORT), as studied in the TARGIT-A and ELIOT trials, offers maximum convenience by delivering radiation in a single session; however, it is associated with higher IBTR rates, and some patients may require additional WBI based on final pathology, which diminishes the convenience advantage. When employing external beam APBI, maintaining a PTV-to-breast volume ratio below 25% is ideal, as a large lumpectomy cavity relative to breast size may favor WBI for better cosmetic outcomes. The FAST-Forward trial, which established 26 Gy in 5 fractions for WBI, has narrowed the convenience gap between WBI and APBI, making the decision between these options more nuanced for many patients.

References

• Vicini FA et al. "Long-term outcomes of accelerated partial breast irradiation: NRG Oncology/NSABP B-39/RTOG 0413 phase III clinical trial." J Clin Oncol. 2019;37(35):3382-3392.
• Strnad V et al. "5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial." Lancet. 2016;387(10015):229-238.
• Coles CE et al. "Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial." Lancet. 2017;390(10099):1048-1060.
• Vaidya JS et al. "Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-A) for early breast cancer: TARGIT-A randomised clinical trial." BMJ. 2020;370:m2836.
• Correa C et al. "Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement." Pract Radiat Oncol. 2017;7(2):73-79.

Read this lecture as Markdown